#Exchange Offer #Denmark #Valby #Lundbeckfond #Lundbeck A/S

Lundbeckfond Invest A/S Launches Voluntary Exchange Offer for A-Shares in H. Lundbeck A/S

In a significant move within the biopharmaceutical sector, Lundbeckfond Invest A/S, a fully owned subsidiary of the Lundbeck Foundation, has announced a voluntary exchange offer targeted at eligible A-shareholders of H. Lundbeck A/S. This strategic initiative indicates the foundation's commitment to enhancing its stake in the company and aligning with its long-term vision of improving brain health.

The announcement, made today, outlines details of the exchange offer and emphasizes Lundbeckfond Invest's position as a major shareholder in Lundbeck. As part of the offer, Lundbeckfond Invest will be reaching out to eligible shareholders, providing them an opportunity to exchange their shares under specific terms and conditions. The complete details regarding the exchange offer, alongside all relevant information and contacts, can be accessed through their official site at www.lundbeckfonden.com/exchangeoffer.

Participation of Lundbeck in the Exchange Program
Additionally, Lundbeck has confirmed its participation in the exchange offer with its own holdings of A-shares. This reciprocal arrangement not only orchestrates an interesting dynamic but also reaffirms Lundbeck’s confidence in the long-term advancement of its mission, which primarily focuses on neurological health solutions. Lundbeck aims to innovate within the realms of psychiatric and neurological treatment, where they have made their mark with over 70 years in neuroscience.

However, it is important to note that the shares involved in this exchange are not registered under the U.S. Securities Act of 1933. As such, these shares cannot be offered or sold within the United States unless properly registered or exempted under the said act. This regulatory stipulation underscores a crucial aspect of the financial landscape impacting what is possible via international share exchanges.

About H. Lundbeck A/S

H. Lundbeck A/S stands out in the biopharmaceutical industry as a pioneer solely committed to brain health. The company is focused on developing transformative medicines aimed at addressing major neurological and psychiatric disorders. Lundbeck’s innovative spirit is crucial in tackling some of the toughest health challenges today, particularly for patients who currently have limited or nonexistent treatment options.

The firm is recognized for its dedication to enhancing health outcomes and quality of life for individuals facing brain disorders, which affect millions globally. Lundbeck employs over 5,000 personnel spread across more than 20 countries, making its products accessible in over 80 nations. This wide reach not only highlights the company's robust operational scale but also its commitment to making a meaningful difference.

This recent exchange offer reaffirms Lundbeck's commitment to its mission while keeping stakeholders engaged in their vision for the future. Lundbeck continues to push boundaries, advancing research, and development initiatives that promise new treatment methodologies and equitable healthcare solutions.

For more information about Lundbeck's products and ongoing initiatives, visit their corporate site at www.lundbeck.com and connect via LinkedIn for the latest updates and engaging content.

For shareholders with questions regarding the exchange offer or needing further assistance, Lundbeckfond Invest positions its representatives to facilitate support and clarity throughout this exchange process. Their contact details, including directly reaching out to Jens Høyer and Anders Crillesen, are available for inquiries, ensuring the lines of communication are open for efficient dialogue.

This latest move by Lundbeckfond Invest represents a promising development for both the Lundbeck Foundation and its shareholders, marking a step forward in investment strategy while amplifying Lundbeck’s unwavering dedication to brain health innovations.